Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.72

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) gapped up before the market opened on Tuesday . The stock had previously closed at $11.72, but opened at $12.43. Zentalis Pharmaceuticals shares last traded at $11.97, with a volume of 21,831 shares.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $46.00 price target on shares of Zentalis Pharmaceuticals in a report on Wednesday, February 28th. Wedbush upped their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Zentalis Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $38.57.

Zentalis Pharmaceuticals Trading Up 0.8 %

The firm has a market cap of $838.63 million, a P/E ratio of -2.58 and a beta of 1.82. The firm has a 50-day simple moving average of $13.81 and a 200-day simple moving average of $13.47.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, February 27th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.09. Research analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the sale, the chief financial officer now directly owns 451,449 shares in the company, valued at $5,164,576.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ZNTL. Eventide Asset Management LLC raised its stake in Zentalis Pharmaceuticals by 47.9% in the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock worth $175,134,000 after acquiring an additional 3,745,936 shares during the last quarter. Vanguard Group Inc. lifted its position in Zentalis Pharmaceuticals by 6.2% during the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock valued at $105,047,000 after purchasing an additional 307,490 shares during the period. Federated Hermes Inc. boosted its holdings in Zentalis Pharmaceuticals by 10.9% in the fourth quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after purchasing an additional 212,872 shares during the last quarter. Decheng Capital LLC purchased a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at $31,809,000. Finally, Wellington Management Group LLP grew its position in Zentalis Pharmaceuticals by 0.5% during the 3rd quarter. Wellington Management Group LLP now owns 1,917,105 shares of the company’s stock worth $38,457,000 after purchasing an additional 8,661 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.